MARKSANS:NSE Marksans Pharma Limited

INR 151.00 6.70 4.643105
Icon

Marksans Pharma Limited (MARKSANS:NSE) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - General | NSE
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

INR 151.00

+6.70 (+4.64)%

INR 72.03B

1.37M

INR 301.00(+99.34%)

N/A

Icon

MARKSANS:NSE

Marksans Pharma Limited (INR)
COMMON STOCK | NSE
INR 151.00
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

INR 72.03B

N/A

INR 151.00

Marksans Pharma Limited (MARKSANS:NSE) Stock Forecast

INR 301.00
(+99.34%)

Based on the Marksans Pharma Limited stock forecast from 1 analysts, the average analyst target price for Marksans Pharma Limited is INR 301.00 over the next 12 months. Marksans Pharma Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Marksans Pharma Limited is Slightly Bullish , which is based on 8 positive signals and 4 negative signals. At the last closing, Marksans Pharma Limited’s stock price was INR 151.00. Marksans Pharma Limited’s stock price has changed by +7.86% over the past week, -4.55% over the past month and +112.23% over the last year.

No recent analyst target price found for Marksans Pharma Limited
No recent average analyst rating found for Marksans Pharma Limited

Company Overview Marksans Pharma Limited

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilep...Read More

https://marksanspharma.com

Grandeur, Mumbai, India, 400053

852

March

INR

India

Adjusted Closing Price for Marksans Pharma Limited (MARKSANS:NSE)

Loading...

Unadjusted Closing Price for Marksans Pharma Limited (MARKSANS:NSE)

Loading...

Share Trading Volume for Marksans Pharma Limited Shares

Loading...

Compare Performance of Marksans Pharma Limited Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for MARKSANS:NSE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Marksans Pharma Limited (Sector: Drug Manufacturers - General )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CIPLA:NSE
Cipla Limited -8.90 (-0.60%) INR1,189.74B 32.09 18.14

ETFs Containing MARKSANS

Symbol Name MARKSANS's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Marksans Pharma Limited (MARKSANS:NSE) Stock

Based on ratings from 1 analysts Marksans Pharma Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 1 buy, sell and hold ratings.

MARKSANS:NSE stock's dividend yield is 0.32%. Our analysis grades MARKSANS:NSE stock's dividend yield at F. This means that MARKSANS:NSE stock's dividend yield is above 30% of the stocks in the Drug Manufacturers - General sector in the NSE exchange. Based on this MARKSANS:NSE may be a poor dividend stock for its sector.

Based on targets from 1 analysts, the average taret price for MARKSANS:NSE is INR 301.00 over the next 12 months. The maximum analyst target price is INR 301 while the minimum anlayst target price is INR 301.

MARKSANS:NSE stock's Price/Earning ratio is 22.84. Our analysis grades MARKSANS:NSE stock's Price / Earning ratio at A+. This means that MARKSANS:NSE stock's Price/Earning ratio is above 0% of the stocks in the Drug Manufacturers - General sector in the NSE exchange. Based on this MARKSANS:NSE may be undervalued for its sector.

The last closing price of MARKSANS:NSE's stock was INR 151.00.

The most recent market capitalization for MARKSANS:NSE is INR 72.03B.

Based on targets from 1 analysts, the average taret price for MARKSANS:NSE is projected at INR 301.00 over the next 12 months. This means that MARKSANS:NSE's stock price may go up by +99.34% over the next 12 months.

We can't find any ETFs which contains Marksans Pharma Limited's stock.

As per our most recent records Marksans Pharma Limited has 852 Employees.

Marksans Pharma Limited's registered address is Grandeur, Mumbai, India, 400053. You can get more information about it from Marksans Pharma Limited's website at https://marksanspharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...